January 4, 2018 / 5:45 PM / 5 months ago

BRIEF-Ultragenyx Announces Update To UX007 Development Program In Long-Chain Fatty Acid Oxidation Disorder Patients

* ULTRAGENYX ANNOUNCES UPDATE TO UX007 DEVELOPMENT PROGRAM IN LONG-CHAIN FATTY ACID OXIDATION DISORDER PATIENTS

* ULTRAGENYX PHARMACEUTICAL INC - EXPECTS THAT DECISION ON A POTENTIAL FILING FOR APPROVAL BASED ON PHASE 2 DATA WILL BE MADE IN MID-2018

* ULTRAGENYX PHARMACEUTICAL - SAFETY PROFILE WAS CONSISTENT WITH WHAT HAS BEEN PREVIOUSLY OBSERVED WITH UX007 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below